Comparing two biopsy needles to diagnose lung cancer and lymphoma
Tests two biopsy needles on lymph nodes in adults with suspected lung cancer or lymphoma.
Plain-language title generated from the registry record
Registry title: Improving Genomic Profiling and Reducing Time to Cancer Treatment Via Targeted Use of Endoscopic Ultrasound
Key facts
- Where
- Næstved, Odense, and Roskilde, DenmarkSee the 3 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a suspected lung cancer or lymphoma and a spot next to the food pipe or stomach that needs a tissue sample taken by ultrasound through the food pipe.
- Age
- 18 years or older
- Sex
- Women and men can join.
- Disease stage
- Suspected lung cancer or lymphoma seen on a chest CT or PET-CT scan, with a lesion next to the esophagus or stomach (for example a lung tumor, enlarged or FDG-avid lymph nodes, or a left liver lobe metastasis).
Main reasons for not taking part
- Another earlier cancer where the scan suggests it has come back
- Blood clotting problems that are not corrected, or blood thinners that cannot be stopped
- Pregnant or breastfeeding women
- Large blood vessels lying between the esophagus or stomach and the target lesion on CT
Read by machine on 12 November 2026.
Where in Denmark
- Department of Medicine, Zealand University Hospital, NæstvedNæstved, DenmarkNo longer taking part
- Department of Respiratory Medicine, Odense University HospitalOdense, DenmarkNo longer taking part
- Department of Medicine, Zealand University Hospital, RoskildeRoskilde, DenmarkNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Zealand University Hospital
- Trial code
- NCT06848738
- Record updated
- 27 February 2025
- Original description
Aim:Read full original descriptionShow less
Improving Genomic Profiling and Reducing Time to Non-small Cell Lung Cancer or Lymphoma Treatment Via Targeted Use of Endoscopic Ultrasound: a Randomized Clinical Trial on the Diagnostic Accuracy of Tissue Sampling With FNA Versus FNB
Aim:
To investigate whether the novel 3rd generation FNB needle provides a better diagnostic accuracy than a standard FNA needle in EUS-B guided diagnosis of common deep seated thoracic malignancies (lung cancer and lymphoma).
Short study description:
Consecutive patients referred due to suspected cancer with enlarged (at least 10 mm in the shortest axis) and/or FDG-avid lymph nodes or other lesions adjacent to the esophagus/stomach (e.g. suspected liver metastasis), thus with an indication for EUS-B, will be randomly assigned for tissue sampling either with a standard 22G FNA needle, or the novel 22G crown-cut FNB needle.
280 patients with suspected lung cancer will be included and inclusion will end when the targeted number of 254 patients (127 in each group) with a final diagnosis of lung cancer is reached.
Likewise, 82 patients with suspected lymphoma will be included until the targeted number of 74 patients (37 in each group) with a final diagnosis of lymphoma or sarcoidosis is reached.
Primary outcome: proportion of patients with a comprehensive diagnostic result in each needle arm for patients with lung cancer and lymphoma / sarcoidosis.
Inclusion: Suspicion of lung cancer or lymphoma based on chest CT or PET-CT; Lesions adjacent to the esophagus/stomach (e.g. lung tumor, enlarged/FDG-avid lymph nodes in mediastinum or retroperitoneum, left liver lobe metastasis).
Exclusion: Other previous cancer with CT or PET-CT suggesting recurrence (e.g. pulmonary metastasis); Uncorrected coagulopathies or anticoagulation treatment that cannot be discontinued; Pregnant or lactating women; CT suggesting interposed large vessels between the esophagus/stomach and target lesion.